Product image of Myditin (Pridinol Mesilate) supplied by GNH India

Myditin

Active Ingredient:
Pridinol Mesilate
Origin:
EU

Myditin (Pridinol Mesilate)

Pridinol mesilate, the active ingredient in Myditin, is a centrally acting muscle relaxant presented as an oral tablet for oral use. It reduces skeletal muscle tone and alleviates muscle spasm, providing relief in adults with acute musculoskeletal pain and other skeletal muscle disorders.

GNH India supplies Myditin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality assurance, regulatory compliance, and reliable logistics for global healthcare providers. Our distribution network adheres to stringent temperature and humidity controls to maintain product integrity during transit.

Manufacturer / TM Owner

Trommsdorff Gmbh & Co. Kg

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Myditin (pridinol mesilate) acts on central anticholinergic pathways to relieve muscle‑related conditions.

  • Muscle spasm: diminishes involuntary skeletal muscle contractions, reducing associated discomfort and functional limitation.
  • Musculoskeletal pain: eases pain arising from acute strain or injury of skeletal muscles, supporting better movement.
  • Skeletal muscle disorders: lowers excessive muscle tone, facilitating improved range of motion in various muscle disorders.

How It Works

  • Pridinol mesilate exerts its effect through central anticholinergic activity. By antagonizing muscarinic receptors in the brainstem and spinal cord, it decreases the excitatory cholinergic input to skeletal motor neurons, leading to reduced muscle tone and suppression of involuntary spasms. This central mechanism operates without significant peripheral anticholinergic effects, allowing targeted muscle relaxation while minimizing systemic cholinergic blockade.

Side Effects

Pridinol mesilate may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Dry mouth: reduced salivary secretion causing oral dryness.
  • Drowsiness: mild sedation affecting alertness.
  • Dizziness: sensation of lightheadedness or imbalance.
  • Nausea: mild gastrointestinal upset.
  • Constipation: decreased bowel motility.
  • Blurred vision: temporary visual disturbances.

Serious or Rare Side Effects

  • Allergic reactions: rash, itching, or swelling indicating hypersensitivity.
  • Severe skin rash: Stevens‑Johnson‑type reactions requiring immediate medical attention.
  • Hepatic dysfunction: elevated liver enzymes or jaundice.
  • Cardiac arrhythmia: irregular heart rhythm potentially serious.
  • Seizures: rare occurrence of convulsive episodes.

Precautions & Warnings

When prescribing Myditin, clinicians should consider several precautionary measures to ensure safe use.

  • Pregnancy: safety not established; avoid unless clearly needed.
  • Breastfeeding: unknown excretion; weigh benefits against potential risks.
  • Renal impairment: use with caution; monitor renal function.
  • Elderly patients: increased sensitivity to CNS effects; start at low dose.
  • Concomitant anticholinergic drugs: may enhance anticholinergic burden.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Avoid Interactions

Pridinol mesilate can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Other central anticholinergics: additive anticholinergic effects may cause severe dryness or confusion.
  • Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis.
  • Alcohol: potentiates CNS depression and sedation.

Moderate Interactions (Monitor Closely)

  • CNS depressants (benzodiazepines, opioids): may increase sedation and respiratory depression.
  • Antihistamines: can enhance anticholinergic side effects.
  • Antidepressants (tricyclics): may augment anticholinergic load.

Frequently Asked Questions

Myditin contains pridinol mesilate, a centrally acting muscle relaxant indicated for the relief of muscle spasm, reduction of acute musculoskeletal pain, and improvement of muscle tone in various skeletal muscle disorders.

Pridinol mesilate works by blocking muscarinic receptors in the central nervous system, which reduces excitatory cholinergic signals to skeletal motor neurons. This central anticholinergic action lowers muscle tone and suppresses involuntary spasms.

The appropriate dose of Myditin is determined by the prescribing healthcare professional based on the patient’s condition, age, renal function, and response to therapy. No fixed dosing regimen is provided here.

Safety data for pridinol mesilate in pregnancy and lactation are limited. It is generally advised to avoid use during pregnancy and breastfeeding unless the potential benefit justifies the potential risk to the fetus or infant.

To order Myditin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with other centrally acting muscle relaxants, pridinol mesilate has a distinct anticholinergic mechanism, which may result in a different side‑effect profile, such as less sedation but a higher likelihood of dry mouth. Choice of agent should be individualized to the patient’s comorbidities and tolerance.

Myditin should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed when not in use.

Myditin is supplied as an oral tablet and is taken by mouth with or without food as directed by the prescriber. Swallow the tablet whole; do not crush or chew unless specifically instructed.

Serious adverse events associated with Myditin include severe allergic reactions, hepatic dysfunction, cardiac arrhythmias, and rare seizures. Patients should seek immediate medical attention if they experience rash, jaundice, irregular heartbeat, or convulsive episodes.

Myditin is contraindicated in patients with known hypersensitivity to pridinol mesilate or any excipients, and it should be used with caution in individuals with severe hepatic impairment, uncontrolled cardiac disease, or those taking other potent anticholinergic agents.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Pridinol Mesilate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT